Amgen (AMGN) Modestly Higher Into Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amgen (AMGN) Price Target Raised to $195 at Jefferies
April 22, 2015 11:41 AM EDTIn a note earlier, Jefferies analyst Eun K. Yang reiterated a Buy rating and boosted his price target on Amgen (NASDAQ: AMGN) to $195.00 (from $182.00) following Q1 results.
Yang commented, "Reported ~18% higher EPS (vs. cons) on ~3% higher product sales & lower OpEx; upped FY15 EPS guidance... More
Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook
April 21, 2015 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q1 EPS of $2.48, $0.38 better than the analyst estimate of $2.10. Revenue for the quarter came in at $5.03 billion versus the consensus estimate of $4.91 billion.
Amgen sees FY2015 EPS of $9.35 - $9.65, versus the consensus of $9.32. Amgen sees FY2015 revenue of $20.9 - $21.3... More
